Evidence map›Paper›PMID 29433514›Full record

ArticleWorld journal of surgical oncology2018

Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study.

Tommi Järvinen, Ilkka Ilonen, Juha Kauppi, Jarmo Salo, Jari Räsänen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 7 pooled it
4.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 7 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Tommi JärvinenDepartment of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, P.O. Box 340 HUS, FIN-00029, Helsinki, Finland. tommi.jarvinen@helsinki.fi.ORCID http://orcid.org/0000-0001-8515-9659
Ilkka IlonenDepartment of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, P.O. Box 340 HUS, FIN-00029, Helsinki, Finland.
Juha KauppiDepartment of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, P.O. Box 340 HUS, FIN-00029, Helsinki, Finland.
Jarmo SaloDepartment of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, P.O. Box 340 HUS, FIN-00029, Helsinki, Finland.
Jari RäsänenDepartment of General Thoracic and Esophageal Surgery, Heart and Lung Center, Helsinki University Hospital, P.O. Box 340 HUS, FIN-00029, Helsinki, Finland.
University of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNutritional deficits, cachexia, and sarcopenia are extremely common in esophageal cancer. The aim of this article was to assess the effect of loss of skeletal muscle mass during neoadjuvant treatment on the prognosis of esophageal cancer patients.

methodsEsophageal cancer patients (N = 115) undergoing neoadjuvant therapy and surgery between 2010 and 2014 were identified from our surgery database and retrospectively analyzed. Computed tomography imaging of the total cross-sectional muscle tissue measured at the third lumbar level defined the skeletal muscle index, which defined sarcopenia (SMI < 52.4 cm2/m2 for men and < 38.5 cm2/m2 for women). Images were collected before and after neoadjuvant treatments.

resultsSarcopenia in preoperative imaging was prevalent in 92 patients (80%). Median overall survival was 900 days (interquartile range 334-1447) with no difference between sarcopenic (median = 900) and non-sarcopenic (median = 914) groups (p = 0.872). Complication rates did not differ (26.1% vs 32.6%, p = 0.725). A 2.98% decrease in skeletal muscle index during neoadjuvant treatment correlated with poor 2-year survival (log-rank p = 0.04).

conclusionLoss of skeletal muscle tissue during neoadjuvant treatment correlates with worse overall survival.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCachexiaCombined Modality TherapyCross-Sectional StudiesEsophageal NeoplasmsEsophagectomyFemaleFollow-Up StudiesHumansMaleMiddle AgedMuscle, SkeletalNeoadjuvant TherapyPrognosisRetrospective StudiesRisk FactorsBody compositionEsophageal neoplasmsMalnutritionSarcopeniaThoracic surgery

Identifiers

PMID29433514
PMCPMC5809976
OpenAlexW2801534684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.